Pharmacogenomics

2.6k papers and 60.5k indexed citations i.

About

The 2.6k papers published in Pharmacogenomics in the last decades have received a total of 60.5k indexed citations. Papers published in Pharmacogenomics usually cover Molecular Biology (872 papers), Pharmacology (807 papers) and Oncology (505 papers) specifically the topics of Pharmacogenetics and Drug Metabolism (792 papers), Drug Transport and Resistance Mechanisms (253 papers) and Pharmacological Effects and Toxicity Studies (196 papers). The most active scholars publishing in Pharmacogenomics are Frances J. Sharom, L. DiAnne Bradford, Simon T. Bennett, Howard L. McLeod, Mikko Niemi, David F. Lewis, Anton A. Komar, Gary Hardiman, Cédric Notredame and G. H. Reed.

In The Last Decade

Fields of papers published in Pharmacogenomics

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Pharmacogenomics. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Pharmacogenomics

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Pharmacogenomics. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Pharmacogenomics with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025